Geoff Meacham is ranked #2460 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Geoff Meacham (Citi) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Geoff Meacham's stock ratings?

About 45% of Geoff's ratings were profitable over a one-year hold, with an average return of -2.7% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Geoff Meacham

Citi

Geoff Meacham

Citi

Wall Street Analyst

★☆☆☆☆

#2460

on 13Foresight · ranked by our own returns

45%

Success Rate

-2.7%

Average Return

42 of 94 calls profitable · -19257.5% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 45% of Geoff Meacham's ratings turned a profit when each position was held for 1 year — averaging -2.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

167 Buy 104 Hold 6 Sell

Geoff's Stock Coverage 80 ratings · 2026-06-20

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
GILD Gilead Sciences	Jun 17, 2026	BUY	Strong Buy -4.8% avg upside 66 analysts	$165.00 33.32% Upside	-1.4%
MRNA Moderna	Jun 17, 2026	HOLD	Hold +6.1% avg upside 38 analysts	$41.00 35.87% Downside	+3.5%
VRTX Vertex Pharmaceuticals	Jun 16, 2026	BUY	Strong Buy -2.6% avg upside 61 analysts	$585.00 29.48% Upside	+1.3%
MRK Merck & Company	Jun 16, 2026	HOLD	Strong Buy +10.7% avg upside 43 analysts	$125.00 9.70% Upside	+0.2%
LLY Eli Lilly & Co	Jun 16, 2026	BUY	Strong Buy -10.5% avg upside 47 analysts	$1500.00 36.49% Upside	-2.1%
ABBV AbbVie	Jun 12, 2026	HOLD	Buy +2.9% avg upside 43 analysts	$230.00 6.29% Upside	-2.9%
FTH Faeth Therapeutics	Jun 11, 2026	BUY	Strong Buy +108.4% avg upside 11 analysts	$55.00 208.71% Upside	·
PFE Pfizer	Jun 07, 2026	HOLD	Buy +34.2% avg upside 45 analysts	$27.00 7.07% Upside	-1.6%
BMY Bristol-Myers Squibb	May 31, 2026	HOLD	Buy +9.1% avg upside 42 analysts	$66.00 22.26% Upside	+0.6%
APGE Apogee Therapeutics	May 28, 2026	BUY	Strong Buy +28.7% avg upside 19 analysts	$125.00 38.22% Upside	+13.6%
RPRX Royalty Pharma	May 26, 2026	BUY	Strong Buy +4.2% avg upside 15 analysts	$66.00 24.58% Upside	-0.3%
REGN Regeneron	May 18, 2026	HOLD	Strong Buy +26.9% avg upside 57 analysts	$700.00 14.68% Upside	-3.3%
MANE Veradermics, Incorporated	May 18, 2026	BUY	Strong Buy +31.9% avg upside 6 analysts	$135.00 43.72% Upside	·
PTGX Protagonist Therapeutics	May 10, 2026	BUY	Strong Buy -22.1% avg upside 19 analysts	$130.00 15.22% Upside	+7.7%
PTCT PTC Therapeutics	May 07, 2026	HOLD	Buy -1.5% avg upside 29 analysts	$75.00 5.07% Downside	+21.8%
AMLX Amylyx Pharmaceuticals Inc	May 07, 2026	BUY	Strong Buy +46.8% avg upside 13 analysts	$20.00 27.60% Upside	+0.3%
SRRK Scholar Rock Holding	May 07, 2026	BUY	Strong Buy +20.1% avg upside 23 analysts	$58.00 22.45% Upside	+1.1%
NVAX Novavax	May 07, 2026	SELL	Buy +154.1% avg upside 20 analysts	$7.00 23.39% Downside	+3.8%
BIIB Biogen	May 04, 2026	HOLD	Strong Buy +25.1% avg upside 51 analysts	$200.00 1.69% Upside	+6.1%
AMGN Amgen	May 01, 2026	HOLD	Buy -11.6% avg upside 57 analysts	$345.00 2.12% Upside	+3.1%
KYMR Kymera Therapeutics	Apr 30, 2026	BUY	Strong Buy +8.9% avg upside 36 analysts	$120.00 32.64% Upside	+10.9%
KNSA Kiniksa Pharmaceuticals	Apr 29, 2026	BUY	Strong Buy -0.2% avg upside 11 analysts	$60.00 8.95% Upside	-1.2%
BNTX BioNTech SE	Mar 11, 2026	BUY	Strong Buy +50.5% avg upside 26 analysts	$130.00 43.02% Upside	+0.1%
VOR Vor Biopharma	Jan 30, 2026	BUY	Buy +199.3% avg upside 17 analysts	$50.00 245.01% Upside	+8.2%
ABOS Acumen Pharmaceuticals	Jan 30, 2026	BUY	Strong Buy +258.9% avg upside 10 analysts	$4.00 76.93% Upside	-9.6%
NAMS NewAmsterdam Pharma Company	Jan 30, 2026	BUY	Strong Buy +56.4% avg upside 18 analysts	$55.00 84.34% Upside	-4.2%
JNJ Johnson & Johnson	Jun 10, 2024	HOLD	Strong Buy -3.5% avg upside 36 analysts	$170.00 25.49% Downside	+9.8%
NMRA Neumora Therapeutics, Inc.	Jun 06, 2024	BUY	Buy +422.4% avg upside 11 analysts	$22.00 1356.97% Upside	-89.7%
BMRN BioMarin Pharmaceutical	Jun 04, 2024	BUY	Strong Buy +72.8% avg upside 52 analysts	$130.00 137.70% Upside	-29.1%
CRBU Caribou Biosciences	Jun 03, 2024	BUY	Strong Buy +581.8% avg upside 12 analysts	$17.00 936.63% Upside	-50.9%
CRSP Crispr Therapeutics AG	May 23, 2024	BUY	Buy +39.1% avg upside 41 analysts	$100.00 84.96% Upside	-33.9%
SANA Sana Biotechnology	May 13, 2024	BUY	Strong Buy +214.8% avg upside 14 analysts	$14.00 344.50% Upside	-77.3%
MLYS Mineralys Therapeutics, Inc.	May 13, 2024	BUY	Strong Buy +82.7% avg upside 12 analysts	$36.00 46.22% Upside	+17.5%
LYEL Lyell Immunopharma	May 13, 2024	BUY	Buy +96.2% avg upside 10 analysts	$9.00 29.41% Downside	-83.1%
PCVX Vaxcyte	May 10, 2024	BUY	Strong Buy +96.1% avg upside 15 analysts	$101.00 96.36% Upside	-52.2%
LIANY LianBio Sponsored ADR	Mar 15, 2024	HOLD	Buy +11232.2% avg upside 4 analysts	—	·
RANI Rani Therapeutics Holdings	Mar 15, 2024	HOLD	Strong Buy +1114.2% avg upside 10 analysts	—	-54.5%
TYRA Tyra Bioscience	Dec 15, 2023	HOLD	Strong Buy +57.9% avg upside 17 analysts	$15.00 47.12% Downside	+10.7%
GSK GlaxoSmithKline	Oct 11, 2023	SELL	Hold -13.9% avg upside 19 analysts	—	-7.3%
VAXX Vaxxinity Inc	Sep 29, 2023	HOLD	Buy +73233.3% avg upside 4 analysts	—	-98.5%
IPSC Century Therapeutics	Sep 29, 2023	HOLD	Strong Buy +132.5% avg upside 11 analysts	—	-19.5%
VIR Vir Biotechnology	Sep 08, 2023	HOLD	Strong Buy +185.4% avg upside 16 analysts	$14.00 52.85% Upside	-29.4%
JANX Janux Therapeutics Inc	Jul 18, 2023	BUY	Strong Buy +217.1% avg upside 21 analysts	$25.00 75.77% Upside	+244.7%
LQDA Liquidia Technologies	Mar 16, 2023	BUY	Strong Buy -28.5% avg upside 15 analysts	$13.00 81.69% Downside	+116.9%
BBIO BridgeBio Pharma	Mar 06, 2023	BUY	Strong Buy +38.7% avg upside 34 analysts	$18.00 72.92% Downside	+78.3%
RCUS Arcus Biosciences	Feb 28, 2023	HOLD	Strong Buy +38.0% avg upside 20 analysts	$23.00 5.32% Downside	+5.2%
LENZ LENZ Therapeutics	Feb 23, 2023	SELL	Buy +284.0% avg upside 17 analysts	$2.00 67.43% Downside	-17.6%
UTHR United Therapeutics	Feb 22, 2023	SELL	Buy -18.7% avg upside 26 analysts	$150.00 71.99% Downside	+10.7%
EDIT Editas Medicine	Feb 22, 2023	HOLD	Buy +407.9% avg upside 33 analysts	$16.00 494.84% Upside	-18.7%
CYTK Cytokinetics	Feb 17, 2023	HOLD	Strong Buy +8.9% avg upside 36 analysts	$49.00 37.79% Downside	+68.2%
INO Inovio Pharmaceuticals	Feb 16, 2023	SELL	Buy +808.3% avg upside 19 analysts	$24.00 2052.43% Upside	+56.2%
BTAI Bioxcel Therapeutics	Nov 14, 2022	BUY	Buy +1918.5% avg upside 12 analysts	$44.00 3566.65% Upside	-74.0%
OMER Omeros	Jun 08, 2022	HOLD	Buy +111.2% avg upside 14 analysts	$4.00 61.12% Downside	+247.2%
PMVP PMV Pharmaceuticals	May 18, 2022	BUY	Strong Buy +1200.9% avg upside 12 analysts	$62.00 5386.70% Upside	-58.8%
ERAS Erasca	May 17, 2022	BUY	Strong Buy +39.0% avg upside 14 analysts	$20.00 46.23% Upside	-53.3%
RGNX RegenXBio	Jan 13, 2022	BUY	Strong Buy +381.4% avg upside 22 analysts	$60.00 669.24% Upside	-7.6%
PRTA Prothena	Oct 08, 2021	HOLD	Buy +160.9% avg upside 14 analysts	$75.00 739.78% Upside	-21.0%
AREN The Arena Group	Jun 08, 2021	HOLD	Strong Buy +709.6% avg upside 12 analysts	—	-24.8%
LARK Landmark Bancorp	Mar 19, 2021	BUY	Strong Buy +20.0% avg upside 1 analyst	$35.24 20.01% Upside	+3.9%
ESPR Esperion	Jan 15, 2021	HOLD	Buy +701.2% avg upside 22 analysts	$35.00 1011.03% Upside	-84.6%
RCKT Rocket Pharmaceuticals	Jan 05, 2021	BUY	Buy +393.7% avg upside 29 analysts	$70.00 1989.56% Upside	-63.7%
BCRX BioCryst	Dec 07, 2020	BUY	Strong Buy +103.3% avg upside 24 analysts	$9.00 0.18% Upside	+69.1%
DMRA Damora Therapeutics	Nov 23, 2020	BUY	Strong Buy +28.3% avg upside 19 analysts	$21.00 1.12% Downside	·
SGMO Sangamo Therapeutics	Sep 08, 2020	BUY	Buy +5844.2% avg upside 16 analysts	$20.00 11361.22% Upside	-3.7%
QTTB Q32 Bio	Jun 25, 2020	BUY	Buy +345.2% avg upside 24 analysts	$30.00 152.10% Upside	-55.1%
TVTX Travere Therapeutics	Feb 25, 2020	HOLD	Strong Buy -16.0% avg upside 22 analysts	$19.00 65.50% Downside	+106.2%
DE:MRK Merck KGaA	Feb 20, 2020	HOLD	Buy +2.2% avg upside 32 analysts	$78.41 41.04% Downside	·
GOSS Gossamer Bio	Dec 03, 2019	BUY	Buy +4379.4% avg upside 17 analysts	$32.00 18947.65% Upside	-64.5%
INCY Incyte	May 03, 2019	HOLD	Buy +1.0% avg upside 47 analysts	$82.00 16.58% Downside	+17.1%
IRWD Ironwood Pharma	May 02, 2019	HOLD	Hold +235.6% avg upside 23 analysts	$13.00 267.17% Upside	-6.1%
DBVT DBV Technologies SA - American	Mar 29, 2019	HOLD	Strong Buy +55.4% avg upside 15 analysts	$8.00 48.44% Downside	-48.8%
ALEC Alector	Mar 29, 2019	BUY	Hold +532.1% avg upside 14 analysts	$27.00 1442.84% Upside	+21.6%
NBIX Neurocrine	Mar 28, 2019	BUY	Strong Buy +7.8% avg upside 37 analysts	$110.00 30.47% Downside	+3.5%
CTMX CytomX Therapeutics	Mar 11, 2019	BUY	Strong Buy +269.6% avg upside 21 analysts	$16.00 442.35% Upside	-41.7%
TSE:BHC Bausch Health Companies	Feb 20, 2019	BUY	Buy +807.0% avg upside 29 analysts	—	·
ALNY Alnylam Pharma	Sep 07, 2017	BUY	Strong Buy +23.6% avg upside 51 analysts	$105.00 62.24% Downside	+50.3%
ZYME Zymeworks	Sep 07, 2017	SELL	Strong Buy +40.3% avg upside 25 analysts	$8.00 65.41% Downside	-87.4%
ENTA Enanta Pharmaceuticals	Oct 23, 2015	SELL	Buy +159.2% avg upside 17 analysts	$16.00 26.41% Upside	-2.5%
AGIO Agios Pharma	Dec 02, 2014	HOLD	Strong Buy +73.2% avg upside 29 analysts	$90.00 163.49% Upside	-34.0%
CLF Cleveland-Cliffs	Sep 17, 2012	HOLD	Buy +8.1% avg upside 20 analysts	—	-45.1%

🔒 75 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Geoff Meacham — Frequently Asked Questions

How accurate are Geoff Meacham's stock ratings?

Based on the calls 13Foresight could measure, about 45% of Geoff's ratings were profitable over a one-year hold, with an average return of -2.7% per rating, or -12.4% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Geoff ranked on 13Foresight?

Geoff Meacham is currently ranked #2460 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Geoff cover?

Geoff most recently has ratings on GILD, MRNA, VRTX, MRK, LLY, ABBV, FTH, PFE, BMY, APGE, RPRX, REGN and 68 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!